Lemang Bio Raises 200M RMB for AI CAR-T

Post LinkedIn

🔥Read original on 36氪

#biotech-funding #cell-therapy #ai-drug-devmeta-10-ai-platformlemang-bio xtalpi meta-10-ai car-t

💡AI CAR-T hits 100% remission at 0.1% standard dose in trials

⚡ 30-Second TL;DR

What Changed

Nearly 200M RMB funding led by Yuecai Zhongyin, XtalPi; old investors add on

Why It Matters

Boosts AI-biotech convergence, potentially slashing CAR-T costs and enabling outpatient treatments for cancers and autoimmune diseases.

What To Do Next

Read Lemang's Lancet Hematology paper on CD19 CAR-T for B-ALL 100% CR data.

Who should care:Researchers & Academics

Key Points

•Nearly 200M RMB funding led by Yuecai Zhongyin, XtalPi; old investors add on
•Funds for CD19 CAR-T Phase I trials, automation, solid tumor CGT
•META platforms reprogram T-cell metabolism via IL-10 for low-dose efficacy
•Clinical wins: 100% CR in B-ALL, 100% remission in SLE at 1/1000 dose

🧠 Deep Insight

Background and context from public sources — not the original article. 7 sources cited.

🔑 Enhanced Key Takeaways

•Leman Biotech previously secured around USD 20 million in angel financing and non-dilutive grants, with new shareholders including Fuho Capital and Yunfan Technology Investment alongside continuing support from Tiantu Capital and XtalPi[1].
•Metabolically enhanced CD19 CAR-T achieved complete remission in more than 20 patients using doses as low as 1% of commercial CAR-T equivalents, potentially reducing production costs and aiding medical insurance inclusion[1].
•The therapy has been presented at major conferences including ASGCT 2024, EHA 2024, and CSCB 2024 annual meeting[1].

🔮 Future ImplicationsAI analysis grounded in cited sources

Lemang Bio's low-dose CAR-T could reduce treatment costs by shortening production cycles

Clinical data shows efficacy at 1% of standard doses in over 20 patients, directly lowering manufacturing expenses and enabling broader reimbursement eligibility[1].

Funding enables solid tumor expansion for META platforms

New capital supports acceleration of metabolically enhanced cell therapies targeting solid tumors beyond initial CD19 applications[1][2].

⏳ Timeline

2024

Presentations of metabolically enhanced CAR-T at ASGCT, EHA, and CSCB conferences

2025

Secured USD 7 million financing plus prior USD 20 million angel and grants for IND and solid tumor research

2026-03

Raised nearly 200M RMB led by Yuecai Zhongyin and XtalPi for Phase I trials and production

📎 Sources (7)

Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.

🔥Read original article on 36氪

📰

Weekly AI Recap

Read this week's curated digest of top AI events →

👉Related Updates

Same topic

Explore #biotech-funding

Same product